JP6346623B2 - 経口投与用の咀嚼可能な組成物およびその製造方法 - Google Patents
経口投与用の咀嚼可能な組成物およびその製造方法 Download PDFInfo
- Publication number
- JP6346623B2 JP6346623B2 JP2015557416A JP2015557416A JP6346623B2 JP 6346623 B2 JP6346623 B2 JP 6346623B2 JP 2015557416 A JP2015557416 A JP 2015557416A JP 2015557416 A JP2015557416 A JP 2015557416A JP 6346623 B2 JP6346623 B2 JP 6346623B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical
- weight
- pectin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 95
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000001814 pectin Substances 0.000 claims description 20
- 235000010987 pectin Nutrition 0.000 claims description 20
- 229920001277 pectin Polymers 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000000465 moulding Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 235000021092 sugar substitutes Nutrition 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 8
- 239000012907 medicinal substance Substances 0.000 description 6
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229960003592 fexofenadine Drugs 0.000 description 4
- -1 flavorings Substances 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 235000012730 carminic acid Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- KQVJZDZLEDQCSD-UHFFFAOYSA-H dialuminum;2-[[4-[ethyl-[(3-sulfonatophenyl)methyl]amino]phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]benzenesulfonate Chemical compound [Al+3].[Al+3].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1.C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1.C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 KQVJZDZLEDQCSD-UHFFFAOYSA-H 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/231—Pectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Confectionery (AREA)
Description
− 0.5〜3.5重量%、好ましくは1〜3重量%の高(メチル)ペクチン、
− 40〜70重量%、好ましくは50〜68重量%のグリセリン、
− 16〜30重量%、好ましくは20〜29重量%の水、
− 0〜2.5重量%、存在するとき、好ましくは0.1〜1.5重量%の少なくとも1種の界面活性剤、
− 1.5〜40重量%、好ましくは2〜30重量%の、代用糖(sugar substitute)、香味料、着色料および/または活性物質からなる群から選択される少なくとも1種の別の成分
を含み、重量百分率は、前記組成物の全重量に対するものであり、前記組成物のpHは、約2.8から約3.2の範囲内である、前記組成物に関する。
− 痛み止め、鎮痛剤、解熱剤、風邪および咳を治療できる分子(特に、鎮咳剤、うっ血除去剤および/または去痰剤)、アレルギーを治療できる分子(抗ヒスタミン剤)、鎮痙剤、抗下痢剤、抗炎症剤(非ステロイド系抗炎症剤(NSAID)など)、血管拡張剤、抗感染症剤、抗ウイルス剤、抗癌剤、抗不安剤、抗てんかん剤、昇圧剤、血圧降下剤、抗片頭痛剤、骨格筋弛緩剤、利尿剤、またはそれらの組合せ。
− ジフェンヒドラミン、クロルフェニラミン、ロラチジン、セチリジン、プソイドエフェドリン、グアイフェネシン、デキストロルファン、ナプロキセン、アスピリン、アセトアミノフェン、イブプロフェン、ケトプロフェン、ドロタベリン、コデインおよびまたはそれらの組合せ。
− ビタミン(A、K、D、E、C、B1、B12)もしくはマルチビタミン組成物、ミネラル(カルシウム塩など)、エストロゲン、不飽和脂肪酸、フラボノイド、植物ステロール、植物抽出物、または他のもの、およびそれらの組合せ。
− 医薬物質の溶解性を高めることができる賦形剤。一例として、シクロデキストリンは、医薬物質と複合体を形成して、その溶解性を高めることができる;
− 医薬物質を緩衝できる賦形剤、例えば、pH6.2のリン酸塩緩衝剤など;
− 医薬物質を腸溶耐性(enteric resistance)のためにコーティングすることができる賦形剤。一例として、腸溶耐性ポリマーは、ポリメタクリレート(Eudragit(登録商標)Lの商品名で販売されるものなど)、セルロースエステル、例えばヒプロメロースアセテートサクシネート(HPMCAS)および/もしくはセルロースアセテートフタレート(CAP)、ならびに/またはポリビニル誘導体、例えばポリビニルアセテートフタレート(PVAP)などの中から選ぶことができる;
− 医薬物質を味覚マスキングのためにコーティングすることができる賦形剤。一例として、味覚マスキング賦形剤は、ヒドロキシプロピルメチルセルロース(HPMC)、ポリビニルピロリドン(PVP)、ポリエチレングリコール(PEG)、ポリメタクリレート、エチルセルロース(EC)、ステアリン酸などの中から選ぶことができる。
− 組成物の味は、適切な代用糖および香味料を添加することによって改変することができ、さらに
− 着色料によって、咀嚼可能な組成物をより魅力的にすることができる。
(i)グリセリン、水を、場合により活性物質および/または界面活性剤と共に混合する工程、
(ii)加熱後に、高(メチル)ペクチンを添加する工程、
(iii)もしあれば、代用糖、香味料および/または着色料を添加する工程、
(iv)工程(ii)で生じた混合物を約60℃から約90℃の範囲の温度に、好ましくは約70℃の温度に加熱する工程、
(v)酸でpHを調整する工程、
(vi)組成物を成形して、ゲル化が起こるまで冷却する工程
を含む、前記製造方法に関する。
医薬組成物の製造を次のように実行した。
− 医薬賦形剤であるβ−シクロデキストリンを共に含む、フェキソフェナジン塩酸塩。
本発明による医薬組成物は、いかなる防腐剤の使用も必要としない。特に、パラベンの添加を回避することができる。この特徴は、本発明による医薬組成物の水分活性を測定することによって証明することができる。
上記のように、成形単位は容易に把持される。この特徴を評価するために、前記単位の硬さをテクスチャーアナライザーで測定した。
テクスチャーアナライザーは、5kgのロードセルを有する直径6mmの円筒型プローブを備えた、Stable Micro Systems(登録商標)製のTA.XT.plus Texture Analyserであった。
モード:圧縮時の力の測定
試験速度=1mm/秒
距離=1mm
トリガタイプ=オート−5.0g
医薬組成物の製造を次のように実施した。
ゲル化後、ゲル化組成物を型から出し、水分活性を測定した。この測定は、実施例1に記載したプロトコルに従って行われた。
硬さを、実施例1に記載したプロトコルに従って測定した。測定の再現性を判断するために、10個のサンプルを試験した。
医薬組成物の製造を次のように実施した。
ゲル化後、ゲル化組成物を型から出し、水分活性を測定した。この測定は、実施例1に記載したプロトコルに従って行われた。
硬さを、実施例1に記載したプロトコルに従って測定した。測定の再現性を判断するために、10個のサンプルを試験した。
Claims (11)
- 経口投与用の組成物であって:
− 0.5〜3.5重量%の高(メチル)ペクチン、
− 50〜68重量%のグリセリン、
− 16〜30重量%の水、
− 0〜2.5重量%の少なくとも1種の界面活性剤、
− 1.5〜40重量%の、代用糖、香味料、着色料および/または活性物質からなる群から選択される少なくとも1種の別の成分
を含み、重量百分率は、前記組成物の全重量に対するものであり、前記組成物のpHは、(約)2.8から(約)3.2の範囲内に含まれる、前記組成物。 - 0.61未満の水分活性を有する、請求項1に記載の組成物。
- 前記組成物のpHは、酸を前記組成物に添加することによって調整される、請求項1または2に記載の組成物。
- 咀嚼可能である、請求項1〜3のいずれか1項に記載の組成物。
- 請求項1〜4のいずれか1項に記載の組成物を含む医薬組成物であって、前記医薬組成物は、場合により少なくとも1種の医薬賦形剤と共に少なくとも1種の活性物質を含み、前記活性物質は、医薬物質である、前記医薬組成物。
- 医薬として使用するための、請求項5に記載の医薬組成物。
- 請求項1〜4のいずれか1項に記載の組成物または請求項5または6に記載の医薬組成物の製造方法であって、以下の工程:
(i)グリセリン、水を、場合により活性物質および/または界面活性剤と共に混合する工程、
(ii)加熱後に、高(メチル)ペクチンを添加する工程、
(iii)もしあれば、代用糖、香味料および/または着色料を添加する工程、
(iv)工程(ii)で生じた混合物を60℃から90℃の範囲の温度に加熱する工程、
(v)酸でpHを調整する工程、
(vi)組成物を成形して、ゲル化が起こるまで冷却する工程
を含む、前記製造方法。 - 工程(ii)の高(メチル)ペクチンの添加は、工程(i)の混合物を35℃から45℃の範囲内に加熱した後に行われる、請求項7に記載の方法。
- pHはクエン酸で調整される、請求項7または8に記載の方法。
- 成形工程は、組成物を型に注入することによって行われる、請求項7〜9のいずれか1項に記載の方法。
- 成形工程は、冷却したベルト上に組成物の液滴を付着させることによって行われる、請求項7〜9のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305172.2 | 2013-02-14 | ||
EP13305172 | 2013-02-14 | ||
PCT/EP2014/052746 WO2014124981A1 (en) | 2013-02-14 | 2014-02-12 | Chewable composition for oral administration and process for preparing thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016507579A JP2016507579A (ja) | 2016-03-10 |
JP6346623B2 true JP6346623B2 (ja) | 2018-06-20 |
Family
ID=47739180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015557416A Active JP6346623B2 (ja) | 2013-02-14 | 2014-02-12 | 経口投与用の咀嚼可能な組成物およびその製造方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9474713B2 (ja) |
EP (1) | EP2956011B1 (ja) |
JP (1) | JP6346623B2 (ja) |
KR (1) | KR20150116861A (ja) |
CN (1) | CN105007750A (ja) |
AR (1) | AR094770A1 (ja) |
AU (1) | AU2014217965B2 (ja) |
BR (1) | BR112015018200B1 (ja) |
CA (1) | CA2900597C (ja) |
HU (1) | HUE038489T2 (ja) |
IL (1) | IL239958A (ja) |
MX (1) | MX359887B (ja) |
PL (1) | PL2956011T3 (ja) |
RU (1) | RU2015138710A (ja) |
SG (1) | SG11201505541VA (ja) |
TW (1) | TWI622408B (ja) |
WO (1) | WO2014124981A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2999937B1 (fr) | 2012-12-21 | 2015-01-09 | Sanofi Sa | Unite solide a haute teneur en fexofenadine et son procede de preparation |
CA3057078A1 (en) * | 2017-03-20 | 2018-09-27 | Bayer Healthcare Llc | Chewable gel products for active pharmaceutical ingredients |
AU2018357886B2 (en) * | 2017-11-02 | 2024-04-18 | Zambon S.P.A. | Pharmaceutical compositions comprising safinamide |
EP3549579A1 (en) | 2018-04-03 | 2019-10-09 | Sanofi Winthrop Industrie | Oral gum formulation and fabrication process thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
BRPI0614231A2 (pt) | 2005-08-05 | 2012-12-11 | Lupin Ltd | composições farmacêuticas de fexofenadina em forma de suspensão oral |
US9155772B2 (en) * | 2008-12-08 | 2015-10-13 | Philip Morris Usa Inc. | Soft, chewable and orally dissolvable and/or disintegrable products |
CN101628117B (zh) * | 2009-08-18 | 2011-02-16 | 北京航洋胶囊技术有限公司 | 一种咀嚼软胶囊皮、咀嚼软胶囊药物及其制备方法 |
PL2512446T3 (pl) * | 2009-12-16 | 2015-08-31 | Shasun Pharmaceuticals Ltd | Kompozycja transdermalnego hydrożelu z deksibuprofenem |
US20120251484A1 (en) * | 2011-03-31 | 2012-10-04 | Cp Kelco Aps | Cold prepared gel and method for making same |
KR101303479B1 (ko) * | 2011-07-28 | 2013-09-06 | (주)씨엘팜 | 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제 |
FR2999937B1 (fr) | 2012-12-21 | 2015-01-09 | Sanofi Sa | Unite solide a haute teneur en fexofenadine et son procede de preparation |
-
2014
- 2014-02-12 CN CN201480008792.5A patent/CN105007750A/zh active Pending
- 2014-02-12 HU HUE14703892A patent/HUE038489T2/hu unknown
- 2014-02-12 EP EP14703892.1A patent/EP2956011B1/en active Active
- 2014-02-12 RU RU2015138710A patent/RU2015138710A/ru not_active Application Discontinuation
- 2014-02-12 KR KR1020157022247A patent/KR20150116861A/ko not_active Application Discontinuation
- 2014-02-12 BR BR112015018200-3A patent/BR112015018200B1/pt active IP Right Grant
- 2014-02-12 US US14/767,527 patent/US9474713B2/en active Active
- 2014-02-12 PL PL14703892T patent/PL2956011T3/pl unknown
- 2014-02-12 SG SG11201505541VA patent/SG11201505541VA/en unknown
- 2014-02-12 JP JP2015557416A patent/JP6346623B2/ja active Active
- 2014-02-12 AU AU2014217965A patent/AU2014217965B2/en active Active
- 2014-02-12 CA CA2900597A patent/CA2900597C/en active Active
- 2014-02-12 WO PCT/EP2014/052746 patent/WO2014124981A1/en active Application Filing
- 2014-02-12 MX MX2015010486A patent/MX359887B/es active IP Right Grant
- 2014-02-13 AR ARP140100449A patent/AR094770A1/es unknown
- 2014-02-14 TW TW103104989A patent/TWI622408B/zh not_active IP Right Cessation
-
2015
- 2015-07-15 IL IL239958A patent/IL239958A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR112015018200B1 (pt) | 2020-11-03 |
CA2900597A1 (en) | 2014-08-21 |
US9474713B2 (en) | 2016-10-25 |
AU2014217965A1 (en) | 2015-08-20 |
RU2015138710A (ru) | 2017-03-20 |
TW201440821A (zh) | 2014-11-01 |
EP2956011A1 (en) | 2015-12-23 |
CN105007750A (zh) | 2015-10-28 |
KR20150116861A (ko) | 2015-10-16 |
TWI622408B (zh) | 2018-05-01 |
CA2900597C (en) | 2021-11-02 |
PL2956011T3 (pl) | 2018-09-28 |
IL239958A (en) | 2017-11-30 |
US20150374622A1 (en) | 2015-12-31 |
EP2956011B1 (en) | 2018-03-28 |
WO2014124981A1 (en) | 2014-08-21 |
HUE038489T2 (hu) | 2018-10-29 |
AU2014217965B2 (en) | 2017-03-23 |
IL239958A0 (en) | 2015-08-31 |
BR112015018200A2 (pt) | 2017-07-18 |
SG11201505541VA (en) | 2015-08-28 |
AR094770A1 (es) | 2015-08-26 |
MX2015010486A (es) | 2015-10-26 |
JP2016507579A (ja) | 2016-03-10 |
MX359887B (es) | 2018-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arya et al. | Fast dissolving oral films: an innovative drug delivery system and dosage form | |
Siddiqui et al. | Fast dissolving tablets: preparation, characterization and evaluation: an overview | |
CA2365844C (en) | Texture masked particles containing an active ingredient | |
EP3154529B1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
JPWO2006070578A1 (ja) | 硬カプセルのバンドシール | |
Juluru | Fast dissolving oral films: A review | |
TW201240679A (en) | Pharmaceutical formulations | |
JP2000508649A (ja) | 速崩解性経口剤形物 | |
JP6346623B2 (ja) | 経口投与用の咀嚼可能な組成物およびその製造方法 | |
Singh et al. | Fast dissolving drug delivery systems: formulation, preparation techniques and evaluation | |
Bhattarai et al. | Fast dissolving oral films: a novel trend to oral drug delivery system | |
EP2263662A1 (en) | Film-like composition | |
A AlHusban et al. | Recent patents and trends in orally disintegrating tablets | |
JP6505721B2 (ja) | 高周波及び損失性被覆粒子を使用した錠剤の製造プロセス | |
KR20170023108A (ko) | 신속 작용 경구 붕해 필름 | |
Dave et al. | Development and evaluation of high loading oral dissolving film of aspirin and acetaminophen | |
JP2020535200A (ja) | 固体シメチコン粒子及びその剤形 | |
WO2017175792A1 (ja) | 速溶出性三次元造形物、速溶出性三次元造形物用フィラメント及び速溶出性三次元造形物用材料 | |
CA2599649A1 (en) | Drug formulations having controlled bioavailability | |
KR100732199B1 (ko) | 저작성 캡슐 및 그 제조 방법 | |
AU2018239993B2 (en) | Chewable gel products for active pharmaceutical ingredients | |
Tambe | Mouth dissolving tablets: An overview of formulation technology | |
Reza et al. | Recent industrial development in oral thin film technology: An overview | |
JP2021520408A (ja) | 経口ガム製剤およびその作製方法 | |
WO2014125052A1 (en) | Pharmaceutical composition for oral administration comprising fexofenadine and process for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161212 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180328 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180515 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6346623 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |